Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER

NCT00719797 is registered in ClinicalTrials.gov with Gruppo Oncologico del Nord-Ovest as lead sponsor.

NCT NCT00719797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00719797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
Lead sponsor
Gruppo Oncologico del Nord-Ovest
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2008
Completion date
Not reported
Enrollment
509 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer